Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection?
Clavien
Pierre-A
PA
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery / Q000821:virology; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006498:Hepatectomy; D006509:Hepatitis B / Q000150:complications; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation; D008297:Male; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins